Skip to main content
. Author manuscript; available in PMC: 2017 Aug 10.
Published in final edited form as: JAMA Oncol. 2015 Jul;1(4):448–454. doi: 10.1001/jamaoncol.2015.0830

Figure 2. Kaplan-Meier Event-Free Survival (EFS) Curves Showing That Higher Levels of Tumor-Infiltrating Lymphocytes (TILs) Result in Better Survival Outcomes and Provide Information Independently of Pathological Complete Response (pCR).

Figure 2

A, Three-year EFS was 88% (95% CI, 82%-92%) for patients whose tumors contained at least 12.5% TILs (the median level of TILs) and 71% (95% CI, 64%-78%) for patients with less than 12.5% TILs (log-rank P < .001). B, Three-year EFS was 97% (95% CI, 88%-99%) for patients whose tumors contained more than 40% TILs and 77% (95% CI, 72%-83%) for those with less than 40% TILs (log-rank P < .001). C, Three-year EFS was 67% (95% CI, 57%-74%) for patients with no pCR and less than 12.5% TILs; 85% (95% CI, 77%-90%) for patients with no pCR and at least 12.5% TILs; 81% (95% CI, 67%-90%) for patients with pCR and less than 12.5% TILs; and 92% (95% CI, 83%-97%) for patients with pCR and at least 12.5% TILs. D, Three-year EFS was 72% (95% CI, 65%-77%) for patients with no pCR and less than 40% TILs; 95% (95% CI, 80%-99%) for patients with no pCR and more than 40% TILs; 85% (95% CI, 76%-91%) for patients with pCR and less than 40% TILs; and 100% for patients with pCR and more than 40% TILs.

HHS Vulnerability Disclosure